Interferon therapy in primary care

Jeanna M. Piper, Tony T S Wen, Elly M J Xenakis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Interferons are proteins produced by human blood cells in response to stimulation (viral infection). The natural roles of interferons are host defense and modulation of the immune system. Therapeutic uses are based on these roles. Interferon-α has been widely used for malignancies, skin conditions, viral infections, and myeloproliferative disorders. Interferon-β is a standard treatment for relapsing multiple sclerosis. Interferon-γ therapy is currently used for chronic granulomatous disease and skin lesions (human papilloma virus related and keloids), but further research is ongoing. Side effects of interferon therapy are common and limit utility. Flulike symptoms are reported by more than 75% and depression by 10-40% of interferon users. Severe adverse effects are less common but may be life threatening, including autoimmune diseases, thrombotic-thrombocytopenic purpura, and acute renal failure. Limited use of interferon therapy during pregnancy has been described, with successful maternal and neonatal outcomes. Use of interferon therapy during early pregnancy is not an indication for termination.

Original languageEnglish (US)
Pages (from-to)163-169
Number of pages7
JournalPrimary Care Update for Ob/Gyns
Volume8
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Interferons
Primary Health Care
Therapeutics
Virus Diseases
Papillomaviridae
Chronic Granulomatous Disease
Keloid
Thrombotic Thrombocytopenic Purpura
Myeloproliferative Disorders
Pregnancy
Skin
Therapeutic Uses
Acute Kidney Injury
Autoimmune Diseases
Multiple Sclerosis
Immune System
Blood Cells
Mothers
Research
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Nursing(all)

Cite this

Piper, J. M., Wen, T. T. S., & Xenakis, E. M. J. (2001). Interferon therapy in primary care. Primary Care Update for Ob/Gyns, 8(4), 163-169. https://doi.org/10.1016/S1068-607X(00)00082-2

Interferon therapy in primary care. / Piper, Jeanna M.; Wen, Tony T S; Xenakis, Elly M J.

In: Primary Care Update for Ob/Gyns, Vol. 8, No. 4, 2001, p. 163-169.

Research output: Contribution to journalArticle

Piper, JM, Wen, TTS & Xenakis, EMJ 2001, 'Interferon therapy in primary care', Primary Care Update for Ob/Gyns, vol. 8, no. 4, pp. 163-169. https://doi.org/10.1016/S1068-607X(00)00082-2
Piper, Jeanna M. ; Wen, Tony T S ; Xenakis, Elly M J. / Interferon therapy in primary care. In: Primary Care Update for Ob/Gyns. 2001 ; Vol. 8, No. 4. pp. 163-169.
@article{496e4d41e498484f9c2488eeaed8b6f5,
title = "Interferon therapy in primary care",
abstract = "Interferons are proteins produced by human blood cells in response to stimulation (viral infection). The natural roles of interferons are host defense and modulation of the immune system. Therapeutic uses are based on these roles. Interferon-α has been widely used for malignancies, skin conditions, viral infections, and myeloproliferative disorders. Interferon-β is a standard treatment for relapsing multiple sclerosis. Interferon-γ therapy is currently used for chronic granulomatous disease and skin lesions (human papilloma virus related and keloids), but further research is ongoing. Side effects of interferon therapy are common and limit utility. Flulike symptoms are reported by more than 75{\%} and depression by 10-40{\%} of interferon users. Severe adverse effects are less common but may be life threatening, including autoimmune diseases, thrombotic-thrombocytopenic purpura, and acute renal failure. Limited use of interferon therapy during pregnancy has been described, with successful maternal and neonatal outcomes. Use of interferon therapy during early pregnancy is not an indication for termination.",
author = "Piper, {Jeanna M.} and Wen, {Tony T S} and Xenakis, {Elly M J}",
year = "2001",
doi = "10.1016/S1068-607X(00)00082-2",
language = "English (US)",
volume = "8",
pages = "163--169",
journal = "Primary Care Update for Ob/Gyns",
issn = "1068-607X",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Interferon therapy in primary care

AU - Piper, Jeanna M.

AU - Wen, Tony T S

AU - Xenakis, Elly M J

PY - 2001

Y1 - 2001

N2 - Interferons are proteins produced by human blood cells in response to stimulation (viral infection). The natural roles of interferons are host defense and modulation of the immune system. Therapeutic uses are based on these roles. Interferon-α has been widely used for malignancies, skin conditions, viral infections, and myeloproliferative disorders. Interferon-β is a standard treatment for relapsing multiple sclerosis. Interferon-γ therapy is currently used for chronic granulomatous disease and skin lesions (human papilloma virus related and keloids), but further research is ongoing. Side effects of interferon therapy are common and limit utility. Flulike symptoms are reported by more than 75% and depression by 10-40% of interferon users. Severe adverse effects are less common but may be life threatening, including autoimmune diseases, thrombotic-thrombocytopenic purpura, and acute renal failure. Limited use of interferon therapy during pregnancy has been described, with successful maternal and neonatal outcomes. Use of interferon therapy during early pregnancy is not an indication for termination.

AB - Interferons are proteins produced by human blood cells in response to stimulation (viral infection). The natural roles of interferons are host defense and modulation of the immune system. Therapeutic uses are based on these roles. Interferon-α has been widely used for malignancies, skin conditions, viral infections, and myeloproliferative disorders. Interferon-β is a standard treatment for relapsing multiple sclerosis. Interferon-γ therapy is currently used for chronic granulomatous disease and skin lesions (human papilloma virus related and keloids), but further research is ongoing. Side effects of interferon therapy are common and limit utility. Flulike symptoms are reported by more than 75% and depression by 10-40% of interferon users. Severe adverse effects are less common but may be life threatening, including autoimmune diseases, thrombotic-thrombocytopenic purpura, and acute renal failure. Limited use of interferon therapy during pregnancy has been described, with successful maternal and neonatal outcomes. Use of interferon therapy during early pregnancy is not an indication for termination.

UR - http://www.scopus.com/inward/record.url?scp=0034936337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034936337&partnerID=8YFLogxK

U2 - 10.1016/S1068-607X(00)00082-2

DO - 10.1016/S1068-607X(00)00082-2

M3 - Article

VL - 8

SP - 163

EP - 169

JO - Primary Care Update for Ob/Gyns

JF - Primary Care Update for Ob/Gyns

SN - 1068-607X

IS - 4

ER -